An Update on Neurodegenerative Disease for Eye Care Providers

      Despite varied underlying pathologic conditions, visual and ocular signs/symptoms are prevalent in all neurodegenerative diseases (NDD). These ocular findings may help differentiate among neurodegenerative processes.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Advances in Ophthalmology and Optometry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kritsilis M.
        • V Rizou S.
        • Koutsoudaki P.N.
        • et al.
        Ageing, cellular senescence and neurodegenerative disease.
        Int J Mol Sci. 2018; 19: 2937
        • Kaeser P.F.
        • Ghika J.
        • Borruat F.X.
        Visual signs and symptoms in patients with the visual variant of Alzheimer disease.
        BMC Ophthalmol. 2015; 15: 65
        • McFarland N.R.
        Diagnostic approach to atypical parkinsonian syndromes.
        Continuum (Minneap Minn). 2016; 22: 1117-1142
        • Gomperts S.N.
        Lewy body dementias: dementia with Lewy bodies and Parkinson disease dementia.
        Continuum (Minneap Minn). 2016; 22: 435-463
        • Ekker M.S.
        • Janssen S.
        • Seppi K.
        • et al.
        Ocular and visual disorders in Parkinson's disease: common but frequently overlooked.
        Parkinsonism Relat Disord. 2017; 40: 1-10
        • Friedman D.I.
        • Jankovic J.
        • McCrary 3rd, J.A.
        Neuro-ophthalmic findings in progressive supranuclear palsy.
        J Clin Neuroophthalmol. 1992; 12: 104-109
        • Hamedani A.G.
        • Gold D.R.
        Eyelid dysfunction in neurodegenerative, neurogenetic, and neurometabolic disease.
        Front Neurol. 2017; 8: 329
        • Yoon W.T.
        • Chung E.J.
        • Lee S.H.
        • et al.
        Clinical analysis of blepharospasm and apraxia of eyelid opening in patients with parkinsonism.
        J Clin Neurol. 2005; 1: 159-165
        • Garland H.G.
        Parkinsonism.
        Br Med J. 1952; 1: 153-156
        • Bonanni L.
        • Anzellotti F.
        • Varanese S.
        • et al.
        Delayed blink reflex in dementia with Lewy bodies.
        J Neurol Neurosurg Psychiatry. 2007; 78: 1137-1139
        • Karson C.N.
        Physiology of normal and abnormal blinking.
        Adv Neurol. 1988; 49: 25-37
        • Roda M.
        • Ciavarella C.
        • Giannaccare G.
        • et al.
        Biomarkers in tears and ocular surface: a window for neurodegenerative diseases.
        Eye Contact Lens. 2020; 46: S129-S134
        • Bologna M.
        • Agostino R.
        • Gregori B.
        • et al.
        Voluntary, spontaneous and reflex blinking in patients with clinically probable progressive supranuclear palsy.
        Brain. 2009; 132: 502-510
        • Ladas A.
        • Frantzidis C.
        • Bamidis P.
        • et al.
        Eye blink rate as a biological marker of mild cognitive impairment.
        Int J Psychophysiol. 2014; 93: 12-16
        • Che N.
        • Yang H.
        Potential use of corneal confocal microscopy in the diagnosis of Parkinson’s disease associated neuropathy.
        Transl Neurodegener. 2020; 9: 28
        • Frost S.
        • Martins R.N.
        • Kanagasingam Y.
        Ocular biomarkers for early detection of Alzheimer's disease.
        J Alzheimers Dis. 2010; 22: 1-16
        • Inoue T.
        • Kawaji T.
        • Tanihara H.
        Elevated levels of multiple biomarkers of Alzheimer's disease in the aqueous humor of eyes with open-angle glaucoma.
        Invest Ophthalmol Vis Sci. 2013; 54: 5353-5358
        • Cesareo M.
        • Martucci A.
        • Ciuffoletti E.
        • et al.
        Association between Alzheimer's disease and glaucoma: a study based on Heidelberg retinal tomography and frequency doubling technology perimetry.
        Front Neurosci. 2015; 9: 479
        • La Morgia C.
        • Ross-Cisneros F.N.
        • Koronyo Y.
        • et al.
        Melanopsin retinal ganglion cell loss in Alzheimer disease.
        Ann Neurol. 2016; 79: 90-109
        • La Morgia C.
        • Ross-Cisneros F.N.
        • Sadun A.A.
        • et al.
        Retinal ganglion cells and circadian rhythms in Alzheimer's disease, Parkinson's disease, and beyond.
        Front Neurol. 2017; 8: 162
        • Koronyo Y.
        • Biggs D.
        • Barron E.
        • et al.
        Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease.
        JCI Insight. 2017; 2: e93621
        • Ortuño-Lizarán I.
        • Beach T.G.
        • Serrano G.E.
        • et al.
        Phosphorylated α-synuclein in the retina is a biomarker of Parkinson's disease pathology severity.
        Mov Disord. 2018; 33: 1315-1324
        • Carelli V.
        • La Morgia C.
        • Ross-Cisneros F.N.
        • et al.
        Optic neuropathies: the tip of the neurodegeneration iceberg.
        Hum Mol Genet. 2017; 26: R139-R150
        • Mendoza-Santiesteban C.E.
        • Gabilondo I.
        • Palma J.A.
        • et al.
        The retina in multiple system atrophy: systematic review and meta-analysis.
        Front Neurol. 2017; 8: 206
        • Gulmez Sevim D.
        • Unlu M.
        • Gultekin M.
        • et al.
        Evaluation of retinal changes in progressive supranuclear palsy and Parkinson disease.
        J Neuroophthalmol. 2018; 38: 151-155
        • Albrecht P.
        • Müller A.K.
        • Südmeyer M.
        • et al.
        Optical coherence tomography in parkinsonian syndromes.
        PLoS One. 2012; 7: e34891
        • Tsokolas G.
        • Tsaousis K.T.
        • Diakonis V.F.
        • et al.
        Optical coherence tomography angiography in neurodegenerative diseases: a review.
        Eye and Brain. 2020; 12: 73-87
        • Molitor R.J.
        • Ko P.C.
        • Ally B.A.
        Eye movements in Alzheimer's disease.
        J Alzheimers Dis. 2015; 44: 1-12
        • Pretegiani E.
        • Optican L.M.
        Eye movements in Parkinson's disease and inherited parkinsonian syndromes.
        Front Neurol. 2017; 8: 592
        • Wilcockson T.D.W.
        • Mardanbegi D.
        • Xia B.
        • et al.
        Abnormalities of saccadic eye movements in dementia due to Alzheimer's disease and mild cognitive impairment.
        Aging (Albany NY). 2019; 11: 5389-5398
        • Galetta K.M.
        • Chapman K.R.
        • Essis M.D.
        • et al.
        Screening utility of the King-Devick test in mild cognitive impairment and Alzheimer disease dementia.
        Alzheimer Dis Assoc Disord. 2017; 31: 152-158
        • Gorges M.
        • Pinkhardt E.H.
        • Kassubek J.
        Alterations of eye movement control in neurodegenerative movement disorders.
        J Ophthalmol. 2014; 2014: 658243
        • Lloyd-Smith Sequeira A.
        • Rizzo J.R.
        • Rucker J.C.
        Clinical approach to supranuclear brainstem saccadic gaze palsies.
        Front Neurol. 2017; 8: 429
        • Irving E.L.
        • Chriqui E.
        • Law C.
        • et al.
        Prevalence of convergence insufficiency in Parkinson's disease.
        Mov Disord Clin Pract. 2016; 4: 424-429
        • Pache M.
        • Smeets C.H.
        • Gasio P.F.
        • et al.
        Colour vision deficiencies in Alzheimer's disease.
        Age Ageing. 2003; 32: 422-426
        • Armstrong R.A.
        Visual symptoms in Parkinson's disease.
        Parkinsons Dis. 2011; 2011: 908306
        • Risacher S.L.
        • WuDunn D.
        • Tallman E.F.
        • et al.
        Visual contrast sensitivity is associated with the presence of cerebral amyloid and tau deposition.
        Brain Commun. 2020; 2: fcaa019
        • Pieri V.
        • Diederich N.J.
        • Raman R.
        • et al.
        Decreased color discrimination and contrast sensitivity in Parkinson's disease.
        J Neurol Sci. 2000; 172: 7-11
        • Yenice O.
        • Onal S.
        • Midi I.
        • et al.
        Visual field analysis in patients with Parkinson's disease.
        Parkinsonism Relat Disord. 2008; 14: 193-198
        • Nishioka C.
        • Poh C.
        • Sun S.W.
        Diffusion tensor imaging reveals visual pathway damage in patients with mild cognitive impairment and Alzheimer's disease.
        J Alzheimers Dis. 2015; 45: 97-107
        • Brewer A.A.
        • Barton B.
        Visual cortex in aging and Alzheimer's disease: changes in visual field maps and population receptive fields.
        Front Psychol. 2014; 5: 74
        • Maia da Silva M.N.
        • Millington R.S.
        • Bridge H.
        • et al.
        Visual dysfunction in posterior cortical atrophy.
        Front Neurol. 2017; 8: 389
        • Valenti D.A.
        Alzheimer's disease: screening biomarkers using frequency doubling technology visual field.
        ISRN Neurol. 2013; 2013: 989583
        • Salamone G.
        • Di Lorenzo C.
        • Mosti S.
        • et al.
        Color discrimination performance in patients with Alzheimer's disease.
        Dement Geriatr Cogn Disord. 2009; 27: 501-507
        • Bertrand J.A.
        • Bedetti C.
        • Postuma R.B.
        • et al.
        Color discrimination deficits in Parkinson's disease are related to cognitive impairment and white-matter alterations.
        Mov Disord. 2012; 27: 1781-1788
        • Frost S.
        • Robinson L.
        • Rowe C.C.
        • et al.
        Evaluation of cholinergic deficiency in preclinical Alzheimer's disease using pupillometry.
        J Ophthalmol. 2017; 2017: 7935406
        • Wu S.Z.
        • Masurkar A.V.
        • Balcer L.J.
        Afferent and efferent visual markers of Alzheimer’s disease: a review and update in early stage disease.
        Front Aging Neurosci. 2020; 12: 572337
        • El Haj M.
        • Roche J.
        • Jardri R.
        • et al.
        Clinical and neurocognitive aspects of hallucinations in Alzheimer's disease.
        Neurosci Biobehav Rev. 2017; 83: 713-720
        • Burghaus L.
        • Eggers C.
        • Timmermann L.
        • et al.
        Hallucinations in neurodegenerative diseases.
        CNS Neurosci Ther. 2012; 18: 149-159
        • Sinclair L.
        • Kumar A.
        • Darreh-Shori T.
        • et al.
        Visual hallucinations in Alzheimer's disease do not seem to be associated with chronic hypoperfusion of to visual processing areas V2 and V3 but may be associated with reduced cholinergic input to these areas.
        Alz Res Ther. 2019; 11: 80
        • Chapman F.M.
        • Dickinson J.
        • McKeith I.
        • et al.
        Association among visual hallucinations, visual acuity, and specific eye pathologies in Alzheimer's disease: treatment implications.
        Am J Psychiatry. 1999; 156: 1983-1985
        • Zarkali A.
        • Adams R.A.
        • Psarras S.
        • et al.
        Increased weighting on prior knowledge in Lewy body-associated visual hallucinations.
        Brain Commun. 2019; 1: fcz007
        • McKeith I.G.
        • Boeve B.F.
        • Dickson D.W.
        • et al.
        Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium.
        Neurology. 2017; 89: 88-100
        • Jankovic J.
        • Aguilar L.G.
        Current approaches to the treatment of Parkinson's disease.
        Neuropsychiatr Dis Treat. 2008; 4: 743-757
        • Linazasoro G.
        • Van Blercom N.
        • Lasa A.
        • et al.
        Levodopa-induced ocular dyskinesias in Parkinson's disease.
        Mov Disord. 2002; 17: 186-187
        • LeWitt P.A.
        Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
        Mov Disord. 1998; 13: 731-734
        • Pandey S.
        • Srivanitchapoom P.
        Levodopa-induced dyskinesia: clinical features, pathophysiology, and medical management.
        Ann Indian Acad Neurol. 2017; 20: 190-198
        • Schumacher-Schuh A.F.
        • Francisconi C.
        • Altmann V.
        • et al.
        Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson's disease.
        Int J Neuropsychopharmacol. 2013; 16: 1251-1258
        • Goetz C.G.
        • Pappert E.J.
        • Blasucci L.M.
        • et al.
        Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations.
        Neurology. 1998; 50: 515-517
        • Jakel R.
        • Stacy M.
        Parkinson’s disease psychosis.
        Res Rev Parkinsonism. 2014; 4: 41-51
        • Burdick D.J.
        • Griffith A.
        • Agarwal P.
        Mydriasis in a Parkinson disease patient on low-dose carbidopa/levodopa.
        Mov Disord. 2013; 28: 295
        • Grandas F.
        • Elston J.
        • Quinn N.
        • et al.
        Blepharospasm: a review of 264 patients.
        J Neurol Neurosurg Psychiatry. 1988; 51: 767-772
        • Dewey Jr., R.B.
        • Maraganore D.M.
        Isolated eyelid-opening apraxia: report of a new levodopa-responsive syndrome.
        Neurology. 1994; 44: 1752-1754
        • Umemura A.
        • Toyoda T.
        • Yamamoto K.
        • et al.
        Apraxia of eyelid opening after subthalamic deep brain stimulation may be caused by reduction of levodopa.
        Parkinsonism Relat Disord. 2008; 14: 655-657
        • Wong J.
        • Lan W.
        • Ong L.M.
        • et al.
        Non-hormonal systemic medications and dry eye.
        Ocul Surf. 2011; 9: 212-226
        • Choi J.H.
        • Kim J.M.
        • Yang H.K.
        • et al.
        Clinical perspectives of Parkinson’s disease for ophthalmologists, otorhinolaryngologists, cardiologists, dentists, gastroenterologists, urologists, physiatrists, and psychiatrists.
        J Korean Med Sci. 2020; 35: e230
        • Hadjikoutis S.
        • Morgan J.E.
        • Wild J.M.
        • et al.
        Ocular complications of neurological therapy.
        Eur J Neurol. 2005; 12: 499-507
        • Oh S.Y.
        • Shin B.S.
        • Lee Y.H.
        • et al.
        Benztropine-induced esotropia and mydriasis.
        J Neuroophthalmol. 2007; 27: 312-313
        • Cruz M.P.
        Pimavanserin (nuplazid): a treatment for hallucinations and delusions associated with Parkinson’s disease.
        P T. 2017; 42: 368-371
        • Mancera N.
        • Wadia H.P.
        Corneal edema associated with systemic dopaminergic agents.
        Cornea. 2019; 38: 1040-1042
        • Rodriguez-Garcia A.
        • Gonzalez-Godinez S.
        • Macias-Rodriguez Y.
        Amantadine corneal toxicity: case report and review of the literature.
        J Ophthalmic Pathol. 2015; 4https://doi.org/10.4172/2324-8599.1000165
        • Yoshinaka A.
        • Chikama T.
        • Kiuchi Y.
        Amantadine can induce intra-epithelial deposition in the cornea.
        Am J Ophthalmol Case Rep. 2020; 19: 100852
        • Xu W.J.
        • Wei N.
        • Xu Y.
        • et al.
        Does amantadine induce acute psychosis? A case report and literature review.
        Neuropsychiatr Dis Treat. 2016; 12: 781-783
        • Enzenauer R.W.
        • Bowers P.J.
        Angle-closure glaucoma after discontinuing donepezil hydrochloride (Aricept).
        J Gerontol A Biol Sci Med Sci. 2005; 60: 1083
        • Goldblum D.
        • Garweg J.G.
        • Böhnke M.
        Topical rivastigmine, a selective acetylcholinesterase inhibitor, lowers intraocular pressure in rabbits.
        J Ocul Pharmacol Ther. 2000; 16: 29-35
        • Kaushik V.
        • Smith S.T.
        • Mikobi E.
        • et al.
        Acetylcholinesterase inhibitors: beneficial effects on comorbidities in patients with Alzheimer’s disease.
        Am J Alzheimers Dis Other Demen. 2018; 33: 73-85
        • Boucart M.
        • Bubbico G.
        • Szaffarczyk S.
        • et al.
        Donepezil increases contrast sensitivity for the detection of objects in scenes.
        Behav Brain Res. 2015; 292: 443-447
        • Szeto J.Y.
        • Lewis S.J.
        Current treatment options for Alzheimer's disease and Parkinson's disease dementia.
        Curr Neuropharmacol. 2016; 14: 326-338
        • Apostolova L.G.
        Alzheimer disease.
        Continuum (Minneap Minn). 2016; 22: 419-434
        • Cerquera-Jaramillo M.A.
        • Nava-Mesa M.O.
        • González-Reyes R.E.
        • et al.
        Visual features in Alzheimer's disease: from basic mechanisms to clinical overview.
        Neural Plast. 2018; 2018: 2941783
        • Folstein M.F.
        • Folstein S.E.
        • McHugh P.R.
        Mini-mental state: a practical method for grading the cognitive state of patients for the clinician.
        J Psychiatr Res. 1975; 12: 189-198
        • Nasreddine Z.
        MoCA TEST. MoCA Montreal cognitive assessment.
        2019 (Available at:) (Accessed December 30, 2020)
        • Roth C.
        Boston diagnostic aphasia examination.
        in: Kreutzer J.S. DeLuca J. Caplan B. Encyclopedia of clinical Neuropsychology. Springer, New York2011https://doi.org/10.1007/978-0-387-79948-3_868 (Available at:)
        • Wu Y.
        • Cho H.J.
        • Panyakaew P.
        • et al.
        Effect of light on blinking in patients with idiopathic isolated blepharospasm.
        Parkinsonism Relat Disord. 2019; 67: 66-71
        • Blackburn M.K.
        • Lamb R.D.
        • Digre K.B.
        • et al.
        FL-41 tint improves blink frequency, light sensitivity, and functional limitations in patients with benign essential blepharospasm.
        Ophthalmology. 2009; 116: 997-1001
        • Woodhead Z.V.
        • Penny W.
        • Barnes G.R.
        • et al.
        Reading therapy strengthens top-down connectivity in patients with pure alexia.
        Brain. 2013; 136: 2579-2591
        • Kerry S.J.
        • Aguilar O.M.
        • Penny W.
        • et al.
        How does iReadMore therapy change the reading network of patients with central alexia?.
        J Neurosci. 2019; 39: 5719-5727
        • Wong B.
        • Lucente D.E.
        • MacLean J.
        • et al.
        Diagnostic evaluation and monitoring of patients with posterior cortical atrophy.
        Neurodegener Dis Manag. 2019; 9: 217-239
        • Yong K.X.X.
        • McCarthy I.D.
        • Poole T.
        • et al.
        Navigational cue effects in Alzheimer's disease and posterior cortical atrophy.
        Ann Clin Transl Neurol. 2018; 5: 697-709
        • Yong K.X.
        • Rajdev K.
        • Shakespeare T.J.
        • et al.
        Facilitating text reading in posterior cortical atrophy.
        Neurology. 2015; 85: 339-348
        • Bansal S.
        • Han E.
        • Ciuffreda K.J.
        Use of yoked prisms in patients with acquired brain injury: a retrospective analysis.
        Brain Inj. 2014; 28: 1441-1446
        • Machan C.M.
        • Chriqui E.
        • Law C.
        • et al.
        Changing vergence function in persons with Parkinson's disease and convergence insufficiency.
        Parkinsonism Relat Disord. 2020; 73: 41-43